Arthneeti
NF

NGL Fine Chem Ltd

Q2 FY27Pharmaceuticals & Biotechnology

NGL Fine Chem Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹159Cr
Net profit
₹16Cr
Margin
17.7%

Based on NGL Fine Chem Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹2,832
Market cap₹1.8K Cr
P/E34.7

The short version

Revenue from Operations for Q2 FY 2026 (quarter ended September 30, 2026):. Quarterly EBITDA (Profit before exceptional items, finance cost, tax, depreciation, amortisation):.

From NGL Fine Chem Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.

How did NGL Fine Chem's revenue grow in the September 2026 quarter?

  • Revenue from Operations for Q2 FY 2026 (quarter ended September 30, 2026):
  • Consolidated: ₹15,870.73 lakhs
  • Standalone: ₹15,743.24 lakhs
  • Revenue from Operations for Q2 FY 2025 (quarter ended September 30, 2025):
  • Consolidated: ₹12,025.83 lakhs
  • Standalone: ₹11,683.93 lakhs
  • Year-on-year growth for the quarter:

2 more points from NGL Fine Chem Ltd's call on revenue

Create a free account to keep reading this call

What happened to NGL Fine Chem's margins in Q2 FY27?

See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.

What capex is NGL Fine Chem planning?

  • The presentation details two renewable energy projects for long-term captive power procurement:
  • A 3.10 MWp solar power project (SPV1) to be developed by a Prozeal-incorporated SPV.
  • A 3.60 MW wind power project (SPV2) similarly to be developed by another Prozeal-incorporated SPV.
  • Total investment for these projects is approximately ₹4.32 Crores.
  • The Company will invest ₹54 Lakhs in the SPV on behalf of its wholly owned subsidiary, Macrotech Polychem Pvt. Ltd.
  • The PPAs for power procurement will be long-term with a 25-year tenure, commencing from the commercial operation date; lock-in period is 15 years.

2 more points from NGL Fine Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is NGL Fine Chem raising money or cutting debt?

See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is NGL Fine Chem's order book?

See what NGL Fine Chem Ltd said on order book & pipeline — free account, 30 seconds.

NGL Fine Chem Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the table below.

NGL Fine Chem Ltd Q2 FY27 results — key figures

NGL Fine Chem Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue159
Operating profit (EBITDA)28
Operating margin17.7%
Profit before tax22
Net profit (PAT)16
EPS (₹)26.30

Source: NGL Fine Chem Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What NGL Fine Chem's management said in earlier quarters

Earlier calls (8)

Others in Pharmaceuticals & Biotechnology this season

  • Kilitch Drugs (Q2 FY27)

    14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Mangalam Drugs (Q2 FY27)

    59% growth. Key results statement takeaways from Mangalam Drugs and Organics Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Astrazeneca Phar (Q2 FY27)

    Year-on-year revenue growth for the quarter: Rs 7,291.0 million vs Rs 5,590.9 million, approximately 30.5% increase. Key results statement takeaways from Astraz

  • Cohance Lifesciences Ltd (Q2 FY27)

    Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9) . Key investor presentation takeaways from Cohance Lifesciences Ltd's Q2 FY27 investor presentation —

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were NGL Fine Chem Ltd Q2 FY27 results?

Revenue from Operations for Q2 FY 2026 (quarter ended September 30, 2026):. Quarterly EBITDA (Profit before exceptional items, finance cost, tax, depreciation, amortisation):.

What is NGL Fine Chem Ltd share price analysis?

NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 34.7 with a market cap of ₹1,750 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem Ltd planning capital expenditure?

The presentation details two renewable energy projects for long-term captive power procurement:.

Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.